In a new set­back, Seres cites Covid im­pact af­ter de­cid­ing to shelve its lead mi­cro­bio­me can­cer pro­gram

Sev­en months af­ter a big, come-from-be­hind win in Phase III for its lead mi­cro­bio­me pro­gram, Seres has an­oth­er set­back to re­port — this time on the can­cer front.

The biotech $MCRB says that its part­nered pro­gram with the Park­er In­sti­tute for Can­cer Im­munother­a­py in metasta­t­ic melanoma is be­ing shelved, cit­ing “chal­lenges” pre­sent­ed by run­ning the study dur­ing the pan­dem­ic. Word is that they came to the de­ci­sion to side­line the ef­fort af­ter 10 pa­tients re­ceived a com­bi­na­tion of SER-401 with Op­di­vo, Bris­tol My­ers’ big PD-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER